FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Delays Hereditary Angioedema NDA Decision

FDA delays a review decision on a KalVista Pharmaceuticals NDA for sebetralstat, indicated for treating hereditary angioedema.

latest-news-card-1
Human Drugs

Keytruda OKd for Head-Neck Cancer Pre/Post-Surgery

FDA approves Mercks Keytruda (pembrolizumab) as the first anti‑PD‑1 therapy that can be given both before and after surgery for adults wit...

latest-news-card-1
Human Drugs

FDA Clinical Hold on Pulmonary Fibrosis Drug

FDA places a clinical hold on a Rein Therapeutics Phase 2 (RENEW) trial of LTI-03 due to agency requests for additional non-clinical information.

latest-news-card-1
Human Drugs

Guide on ANDA Pre-Submission Facility Correspondence

FDA posts a final guidance entitled ANDAs: Pre-Submission Facility Correspondence (PFC) Related to Prioritized Generic Drug Submissions.

latest-news-card-1
Marketing

Senators Introduce Bill to Ban DTC Drug Advertising

Senators Bernie Sanders (I-VT) and Angus King (I-ME) introduce legislation that would ban direct-to-consumer drug advertising.

latest-news-card-1
Biologics

Oncologic Panel to Review Multiple Myeloma BLA

FDA schedules a 7/17 meeting of its Oncologic Drugs Advisory Committee to review and vote on a GSK BLA for Blenrep (belantamab mafodotin) for treating...

latest-news-card-1
Medical Devices

Medtronic Newport Ventilator Recall Class 1

FDA says a Medtronic recall of specified Newport ventilators is Class 1.

Biologics

Questions Raised on New ACIP Members

The Associated Press reports that questions are being raised about some new members appointed to the CDC Advisory Committee on Immunization Practices ...

latest-news-card-1
Human Drugs

Capricor Gets Form-483 After BLA Facility Inspection

A recent FDA pre-license inspection of Capricor Therapeutics San Diego manufacturing facility for investigation cell therapy Deramiocel results in a F...

latest-news-card-1
Human Drugs

FDA Approves UroGen Bladder Cancer Therapy

FDA approves a UroGen Pharma NDA for Zusduri (mitomycin intravesical solution) for adult patients with recurrent low-grade intermediate-risk non-muscl...